Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01778634 · ClinicalTrials.gov registry record · Phase 2

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

A Phase 2 study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target

NCT01778634: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.

NCT01778634 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 121 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01778634, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether intravenous azithromycin is effective in eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks gestation.

Primary Outcome

Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).

Interventions

  • DRUG Placebo
  • DRUG Azithromycin

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2013-07
Est. Completion 2020-11-03
Phase Phase 2
University of Maryland, Baltimore

560 total trials

What the finished NCT01778634 record still lists

NCT01778634 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01778634 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01778634 about?

NCT01778634 is a clinical study titled "Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants". The purpose of this study is to determine whether intravenous azithromycin is effective in eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks gestation.

What is the current status of trial NCT01778634?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2013-07. Estimated completion is 2020-11-03.

What interventions are being tested in trial NCT01778634?

The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).

Who is sponsoring clinical trial NCT01778634?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01778634's enrollment target sits among peer trials

121 567th of 2000 higher than 1,432 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01778634, the US trial registry maintained by the National Library of Medicine. NCT01778634 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.